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Abstract
In patients with a functionally univentricular heart, the Fontan strategy achieves
separation of the systemic and pulmonary circulation and reduction of
ventricular volume overload. Contemporary modifications of surgical
techniques have significantly improved survival. However, the resulting Fontan
physiology is associated with high morbidity. In this review, we discuss the
state of the art of the Fontan strategy by assessing survival and risk factors for
mortality. Complications of the Fontan circulation, such as cardiac arrhythmia,
thromboembolism, and protein-losing enteropathy, are discussed. Common
surgical and catheter-based interventions following Fontan completion are
outlined. We describe functional status measurements such as quality of life
and developmental outcomes in the contemporary Fontan patient. The current
role of drug therapy in the Fontan patient is explored. Furthermore, we assess
the current use and outcomes of mechanical circulatory support in the Fontan
circulation and novel surgical innovations. Despite large improvements in
outcomes for contemporary Fontan patients, a large burden of disease exists in
this patient population. Continued efforts to improve outcomes are warranted.
Several remaining challenges in the Fontan field are outlined.
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Introduction
Functionally univentricular congenital heart disease (CHD), 
in which only one ventricle is fully developed, poses a 
complex clinical problem. Estimates of the incidence of this 
disease entity range from 0.08 to 0.4 per 1,000 births1–3. 
Functionally univentricular CHD entails different morphological 
diagnoses, the most common of which are hypoplastic left heart 
syndrome (HLHS) (25 to 67% of functionally univentricular 
hearts), tricuspid atresia (15 to 24%), and double inlet left ventri-
cle (14 to 18%)1,3–5. It is estimated that currently there are about 
22,000 patients in Europe and about 50,000 in the US6. Recent 
advancements in prenatal screening have increased the rates 
of prenatal diagnosis and possibly termination of pregnancy in 
patients with univentricular hearts1,7. Despite the low incidence, 
improvements in treatment have reduced the mortality to 
the point where a large number of patients survive into adulthood.
Palliation can be achieved with the Fontan strategy. A series 
of operations is performed to palliate the adverse effects of a 
univentricular heart. The Fontan strategy refers to the landmark 
surgery for tricuspid atresia by Fontan and Baudet8. In the “early 
days” of this procedure, it was attempted to replace the func-
tion of the right ventricle with the right atrium by connecting 
the right atrium to the pulmonary artery. Although short-term 
results were unprecedented, this strategy caused dilation of the 
right atrium, resulting in arrhythmia and thromboembolism 
due to sluggish blood flow9. Modifications of this surgery 
are referred to as atriopulmonary connections (APCs). In a 
later era, de Leval et al. found that atrial contractions did not 
contribute significant power to the APC circuit and proposed the 
intra-atrial lateral tunnel (ILT), a transatrial connection using 
an intra-atrial baffle connecting the inferior caval vein to the 
pulmonary artery in a more energetically favorable manner10. 
Currently, most centers employ an extracardiac conduit (ECC), 
a prosthetic conduit that bypasses the atrium completely. Both 
ILT and ECC are referred to as total cavopulmonary connection 
(TCPC) Fontan modifications.
A Fontan circuit was originally created in a single surgical 
setting. This resulted in relatively high mortality. A staged TCPC, 
in which a series of operations is performed at different ages, is 
the current standard of care. These operations are tailored to 
the individual anatomy of the patient. First, the single ventricle 
(SV) needs to be connected to the aorta, which may require 
extensive surgery, such as the Norwood procedure for HLHS. 
At about 3 to 6 months of age, a partial cavopulmonary 
connection (PCPC), connecting the superior caval vein to the 
pulmonary artery (that is, bidirectional Glenn procedure), is 
performed. Completion of the TCPC is usually performed 
between 18 months and 4 years of age4. The connections and 
circulatory pattern after these operations are illustrated in Figure 1.
These patients require a lifetime of highly specialized care and 
significant health-care resources. In Oceania, the mean hospital 
Figure 1. Illustration of the anatomic relationships following partial cavopulmonary connection (A) and total cavopulmonary connection (B) 
palliation. IVC, inferior vena cava; PA, pulmonary artery; SV, single ventricle; SVC, superior vena cava. This figure has been reproduced with 
permission from Kerlo et al. and Springer Nature11.
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costs across all stages of palliation are about $200,000 per 
patient12. Following Fontan palliation, hospital admission 
rates for patients are eight times higher than for the general 
population13, and both length of stay and hospital costs are higher 
compared with those of other CHDs, including tetralogy of 
Fallot14–16.
Physiology
In unpalliated univentricular CHD, cyanosis occurs because 
of mixing of saturated and unsaturated blood in the heart. 
The SV is also exposed to volume overload as it drains both 
systemic and pulmonary venous return at the same time. The 
Fontan strategy reduces volume overload and restores normox-
emia. Following PCPC surgery, some volume unloading of the 
SV is achieved. Following TCPC, the volume load of the SV is 
further reduced17. Furthermore, after TCPC, the systemic and 
pulmonary blood flows are connected in series rather than 
parallel as before this strategy has been deployed. This comes 
at the expense of the lack of a ventricle supplying energy to 
the pulmonary circulation. This is illustrated in Figure 2. The 
SV provides the energy needed to attain blood flow through 
the systemic as well as the pulmonary vascular bed and is 
subjected to increased afterload. After TCPC, central venous 
pressures are higher than normal. Pulsatility in the pulmonary 
artery is mostly lost and there is preload insufficiency of the SV. 
This highly abnormal circulation is called the Fontan circula-
tion. The resulting physiology has been referred to as a “Fontan 
paradox”, where systemic venous pressure is high in the pres-
ence of relative pulmonary artery hypotension18. This might 
augment lymphatic outflow and impede lymphatic inflow from the 
thoracic duct. Several complications of the Fontan strategy 
have been linked to abnormalities in lymphatic drainage. 
Because of the multiple inherent hemodynamic challenges of 
the Fontan circulation, it is generally considered a palliative 
procedure19.
The aim of this article is to provide an overview of current 
outcomes, treatment options, and remaining challenges to 
improve outlook for patients with univentricular heart disease.
State of the art
Overall survival
Survival following the Fontan procedure has increased 
dramatically in the past few decades. We will discuss data from 
Figure 2. Scheme of pressures in the normal circulation (A) and the Fontan circulation (B). This scheme illustrates the effects of the lack 
of a prepulmonary pump in the Fontan physiology. Red represents oxygenated blood and blue represents deoxygenated blood. Ao, aorta; 
CV, caval veins; LA, left atrium; LV, left ventricle; P, pulmonary circulation; PA, pulmonary artery; RA, right atrium; RV, right ventricle; S, systemic 
circulation; V, single ventricle. This figure has been reproduced with permission from Gewillig and Brown and the British Medical Journal 
Publishing Group Ltd20.
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recently published reports of large cohorts with long follow-up 
intervals. An overview of studies assessing survival is 
presented in Figure 3, obtained from Kverneland et al.21.
In a recent study from Oceania, perioperative mortality decreased 
from 8% between 1975 and 1990 to 1% in 2001–201022. 
In this cohort, early Fontan takedown occurred in 2% of 
patients. Ten-year survival among patients discharged with a 
Fontan circulation was 89% following APC and 97% for both 
ECC and ILT23. Survival at 25 years was 76%. This group was 
composed only of APC patients.
In a retrospective study from the Mayo Clinic of 40 years and 
1,052 Fontan patients, overall survival rates were 74% at 10 
years, 61% at 20 years, and 43% at 30 years24. Survival was 
significantly higher in later surgical eras, and 10-year survival was 
95% for patients operated on after 2001. Interestingly, patients 
operated on with the ECC technique showed better overall 
survival over ILT. It should be taken into account that patients 
with cardiac defects with worse prognosis were more frequently 
operated on using the ILT technique.
A Danish national registry described outcomes for SV 
patients from 1977 to 20091. Fifty percent of patients died 
before Fontan completion. Overall survival improved in later 
birth eras. Five-year survival for any univentricular CHD 
increased from 22% in 1977–1989 to 51% in 2000–2009.
One should note that follow-up studies after Fontan pro-
cedures reflect results of an earlier surgical era and do not 
necessarily represent the outlook of Fontan patients undergoing 
surgery in the current era.
Determinants of survival
Several factors have been associated with survival after the 
Fontan procedure. Of preoperative factors, male gender23 
and specific CHD diagnosis, most strikingly for HLHS25, 
have been associated with worse long-term survival. Periop-
erative risk factors for mortality include APC type procedure, 
earlier surgical era, older age at procedure, concomitant valve 
replacement, and prolonged postoperative pleural effusion25. 
Postoperative factors that affect survival include elevated 
central venous pressure and lower arterial saturation26; 
imaging-derived parameters such as lower global longitudinal 
strain on echocardiography and higher end-diastolic volume 
measured by magnetic resonance imaging (MRI)25; peak heart 
rate and peak oxygen uptake during cardiopulmonary exercise 
testing25,27,28; and serum levels of sodium, creatinine, and brain 
natriuretic peptide25,29,30.
Cardiac complications
Although survival following Fontan completion has increased 
over time, the Fontan strategy has been associated with 
important morbidity, most likely related to extensive surgical 
procedures and the highly abnormal circulatory state after these 
procedures. In recent cohorts, event-free survival has ranged 
from 59 to 81% at 15 years23,31.
The most commonly reported event is cardiac arrhythmia. 
Supraventricular tachycardia (SVT) contributes significantly to 
Figure 3. Survival following Fontan completion. Each line represents a study assessing survival at multiple time points and is colored by 
surgical era. Dots represent Kaplan-Meier survival estimates. Studies marked with an asterisk show survival curves for death, transplant, or 
Fontan revision; others show survival curves for only death. This figure has been reproduced with permission from Kverneland et al. and John 
Wiley and Sons21.
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late mortality in Fontan patients32. SVT has been associated with 
Fontan type; the highest risk is for APC type, followed by ILT, 
and the lowest is for ECC23,33. Results may have improved for 
the ILT technique after introduction of the prosthetic 
modification35. The incidence of SVT increases during follow-up, 
and after 20 years of follow-up, 10 to 60% of patients 
have experienced some form of SVT34,35.
Failure of the Fontan circulation can occur even in long-standing 
uncomplicated Fontan circulations. The definition of Fontan 
failure varies but generally includes excessive constitutional 
limitations of the Fontan physiology, abnormal parameters of 
hemodynamic function, poor functional status, or the pres-
ence of Fontan sequelae36. Fontan failure occurs in 2 to 13% 
of patients, depending on definitions and follow-up period36. A 56% 
25-year freedom of Fontan failure for APC connections has been 
reported23.
Extracardiac complications
Abnormalities of coagulation. Blood flow can be slow in the 
Fontan circuit because of the absence of a prepulmonary pump. 
This promotes coagulation. Furthermore, coagulation factor 
abnormalities have been described in the SV patient, even before 
PCPC palliation37. Thromboembolic events are more common 
following APC surgery than TCPC37. The prevalence of thrombi 
is particularly high in those who develop atrial arrhythmias38. Up 
to 65% of thrombi are detected within the first year following 
TCPC (early thromboembolic events)39. Early thromboembolic 
events probably relate to perioperative factors, such as 
extracorporeal membrane oxygenation (ECMO) use and altered 
hemodynamics. Beyond 10 years after Fontan completion, inci-
dence of late thromboembolism steadily increases39. Reports 
of the incidence of thromboembolism are complicated by 
different definitions and methods of detection. Studies report 
incidences of late thromboembolism of between 1 and 25%31,40. 
Silent thrombi are detected with transesophageal echocardi-
ography in up to 33% of patients41. Thromboembolic events 
have been reported to account for 8% of Fontan deaths42.
Liver function abnormalities, cirrhosis, and even hepatocellular 
carcinoma have been reported following Fontan surgery43. The 
elevated systemic venous pressures encountered in the Fontan 
circulation lead to chronic venous congestion in the liver. How-
ever, the exact mechanism for Fontan-associated liver disease 
remains unknown, as does how best to monitor progression44,45. 
The American College of Cardiology recently provided a 
position statement on the subject, advising laboratory and 
imaging screening at least every 3–5 years in children and at 
least every 1–3 years in adult Fontan patients46. Preventive 
strategies need to be developed.
Protein-losing enteropathy (PLE) is a devastating complication 
of the Fontan circulation in which loss of protein in the 
gastrointestinal tract occurs, leading to low albumin levels, 
edema, pleural effusions, and ascites. Incidences of between 3 
and 29% have been reported24,31,35,47. It is thought to be caused, 
in part, by impairments in the lymphatic drainage. Hepatoduo-
denal lymphatic connections exist in some patients as a normal 
anatomic variant, which might induce competition in lymphatic 
flow in the presence of elevated venous pressure, diverting 
lymphatic flow to the gastrointestinal tract.
Plastic bronchitis is a serious pulmonary complication of the 
Fontan circulation in which large gelatinous casts are formed 
in the airways. It is thought to be related to abnormal lymphatic 
drainage directly into the airways, resulting in cast formation. 
Reported incidences range from 0.5 to 4%48–50.
Chronic kidney disease is estimated to be present in up to 
50% of adult Fontan patients and is associated with adverse 
outcomes30,51. With the increasing availability of cystatin 
C-determined glomerular filtration rate (GFR), a muscle mass-
independent estimate, the prevalence of clinically significant 
renal dysfunction appears to be lower52. GFR estimates based 
on serum creatinine concentrations probably overestimate renal 
function in Fontan patients51.
Psychological, psychiatric, and cognitive defects have been 
described in Fontan patients. Cerebral MRI has shown mor-
phological differences in some cerebral structures of Fontan 
patients compared with those of healthy controls53,54. Interest-
ingly, the pituitary gland, supplied by a portal venous system 
similar to the liver, appears to be enlarged following Fontan 
surgery55. The relevance of this possible congestion on the 
endocrine system remains unclear.
Re-interventions
Many patients require additional surgical and catheter-based 
interventions following Fontan completion. Twenty-year free-
dom of re-operation following TCPC procedures in recent eras 
ranges from 86 to 92%56. In older cohorts, higher re-operation 
rates have been reported24,57,58. The most common surgical 
re-intervention procedures, in order of incidence, are pacemaker 
implantation in 9 to 23% of patients23,24, Fontan revision or 
conversion in 3 to 18% of patients9,24,59, and atrioventricular (AV) 
valve repair in 1 to 14% of patients24,59,60.
Fontan conversion, from APC to TCPC, can improve func-
tional status and exercise tolerance in the failing Fontan 
circulation61. AV valve repair after Fontan completion is 
considered in patients with moderate to severe regurgitation, but 
survival following successful repair remains inferior to that of 
patients without prior AV regurgitation62,63.
For several reasons, re-interventions by catheter may be 
required. A fenestration in the atrial tunnel, inducing a right-
to-left atrial shunt, can be created during surgery to decrease 
systemic venous pressure, increase ventricular preload, and 
improve cardiac output at the cost of lower arterial saturation. This 
fenestration sometimes closes spontaneously or can be closed 
via catheter at a later time64.
Hemodynamically significant obstruction in the Fontan pathway 
may occur, most commonly in the left pulmonary artery57,65. 
In the absence of a prepulmonary pump, this can severely 
affect the Fontan circulation, and obstructions are routinely 
dilated or stented.
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Systemic to pulmonary venous collaterals can produce a 
right-to-left shunting which often worsens in time. Coiling of 
these collaterals is routinely performed in some centers, although 
no survival benefit has been demonstrated66.
Aortopulmonary collaterals are common in the Fontan circula-
tion. They increase pulmonary blood flow but induce a volume 
overload on the SV and might increase pulmonary artery 
pressure, limiting flow from the caval veins65. During exercise, 
aortopulmonary flow increases, possibly augmenting loading 
conditions of the ventricle67. A large aortopulmonary collateral 
burden has been associated with worse short-term outcomes68. No 
clear consensus regarding the long-term effects and management 
of these collaterals exists65.
Catheter ablation of an arrhythmogenic substrate is common. 
Long-term success rates vary between 15 and 72%69,70.
The reported incidence of catheter-based interventions (that 
is, excluding diagnostic cardiac catheterization without 
intervention) varies heavily; 3 to 65% of patients require at 
least one additional catheter intervention following Fontan 
completion31,56,57,59,71. The most common catheter interventions 
are fenestration closure (10 to 64% of patients with a fenestra-
tion require catheter-based fenestration closing56,57,59,72), occlusion 
of veno-venous or aortopulmonary collaterals (incidence 
of 10 to 20%)57,59, and stenting and dilation of (all types of) 
obstructions in the Fontan pathway (incidence of 6 to 19%)57,59,73.
Other outcomes and functional status
Most studies report a diminished quality of life in Fontan 
patients compared with healthy controls74–78. Physical and 
emotional functioning are the most severely affected 
domains74,79. Low perceived health status can lead to unnecessary 
restrictions in daily life. Furthermore, increased rates of devel-
opmental disorders and lower intelligence scores have been 
reported in the Fontan population53,76.
Fontan patients have a moderately decreased exercise capacity 
compared with healthy controls80. Mean peak oxygen uptake 
ranges from 61 to 74% of predicted values80–82. A small frac-
tion of Fontan patients have normal exercise capacity83. Exercise 
capacity in the Fontan patient has been shown to decrease over 
time81,82. Exercise capacity is predictive of hospital admissions, 
quality of life, and late mortality25,28,79,82. Exercise training can 
be done successfully in Fontan patients and can improve 
quality of life, functional class, and health perception in a 
short-term follow-up84–87. Whether exercise training has a role 
in optimizing long-term outcome is currently not clear84,86–89. 
Resistance training can be used to increase muscle mass. In the 
Fontan patient, this could augment peripheral venous return, 
augment ventricular preload, and improve cardiac output90. 
Similarly, a benefit of inspiratory muscle training has been 
demonstrated91.
Despite high morbidity and suboptimal outcomes, most 
patients with a well-functioning Fontan circulation manage 
to lead fulfilling lives, are employed, may attain academic 
achievements, can participate in sports, and are able to successfully 
carry pregnancy to term92–94.
Assessment techniques
Fontan patients are routinely assessed for health and 
functional status. Diagnostic cardiac catheterization has been 
standard practice in the pre-TCPC evaluation, as it provides 
excellent anatomic and necessary hemodynamic information 
regarding the pulmonary artery pressure, pulmonary vascular 
resistance, and end-diastolic SV pressure95. There is recent 
interest in omitting cardiac catheterization in the pre-TCPC 
assessment for low-risk SV patients95–97. No consensus regarding 
this policy has been reached, as long-term outcomes are 
currently unavailable. Catheter-based interventions are discussed 
above.
Cardiac magnetic resonance imaging (CMR) is routinely 
performed during follow-up after TCPC, particularly to assess 
ventricular size and function and to quantify large vessel flow, 
including the amount of collateral flow98–102. Death and (being 
listed for) heart transplantation have been associated with higher 
end-diastolic volume index (EDVi) (>125 mL/m2) as assessed 
with CMR in adolescents with a Fontan circulation103,104. 
Combined with a computational fluid dynamics approach, 
CMR might provide very useful information on the Fontan 
circulation and can aid in the evaluation of modifications in 
treatment strategies104,105.
Echocardiographic strain measurements have been shown to 
predict survival in the Fontan population and predict length of 
hospital stay following TCPC104,106. Assessment of ventriculo-
arterial (VA) coupling may be another important parameter, 
as it is independent of the (often impaired) ventricular load. VA 
coupling has been shown to be suboptimal in some Fontan 
populations107. Currently, VA coupling has not been associated 
with long-term outcomes in the Fontan population.
Lymphangiography could play an important role in the 
management of Fontan complications with a suspected lymphatic 
pathogenesis, such as PLE and plastic bronchitis. In patients 
with PLE or plastic bronchitis, increased diameters of major 
lymphatic vessels have been noted108. Abnormal lymphatic depo-
sitions in the lungs and liver have been visualized in patients 
with plastic bronchitis and PLE, respectively109,110.
Medical therapy
Anticoagulation, in the form of anti-platelet drugs or vitamin 
K antagonists (VKAs), is commonly indicated considering 
the increased risk for thromboembolic events, as discussed 
above in the “Extracardiac complications” section111. A meta-
analysis by Alsaied et al. showed that both acetylsalicylic acid 
and VKA were equally effective in preventing thromboem-
bolic complications112. However, if international normalized 
ratio (INR) is not properly controlled, outcomes on VKA are 
worse compared with acetylsalicylic acid113. Novel oral anti-
coagulants (NOACs) do not require frequent monitoring 
and have mostly outperformed VKA in the adult population. 
Thirty-day outcomes following NOAC initiation show no major 
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adverse events in the adult CHD population114. However, no 
NOAC agent currently has US Food and Drug Administration 
approval for use in children.
Medical prevention of circulatory failure in the Fontan 
circulation
Various medications have been assessed in the management of 
Fontan failure. No studies have shown benefit of angiotensin- 
converting enzyme (ACE) inhibitor therapy on survival, 
ventricular function, or cardiopulmonary exercise outcomes115,116.
Vasodilator drugs have been used to lower pulmonary vascular 
resistance117,118. Sildenafil has increased ventricular function, 
exercise capacity, and New York Heart Association (NYHA) 
status after 6 weeks of follow-up119,120. The effects of bosentan, 
an endothelin antagonist, in the Fontan population have 
varied121–126. No long-term survival benefit of vasodilator therapy 
has yet been demonstrated119.
Mechanical circulatory support for the failing Fontan 
circulation
The failing Fontan circulation can be supported by mechanical 
assist devices. Despite increasing use and the development of 
novel devices specifically for the pediatric and CHD popula-
tion, experience in this population is still limited127. Mechanical 
support devices are mostly used as a bridge to transplant 
in the failing Fontan128. Recent reports showed a 60% 12-
month survival in 48 Fontan patients with a ventricular 
assist device, proving viability of longer mechanical circu-
latory support129,130. A total biventricular artificial heart, the 
SynCardia, has been used to bridge a failing Fontan patient 
to transplant131. A registry of mechanical circulatory support 
specifically for SV patients has been initiated132. Currently, 
mechanical circulatory support in Fontan patients is associated 
with worse survival compared with mechanical circulatory 
support patients with a biventricular circulation133–135.
Cardiac transplantation
Cardiac transplantation is the only treatment that truly 
corrects Fontan physiology, and it is employed in the failing 
Fontan circulation. In large cohorts, 1.6 to 3.6% of patients 
ultimately underwent cardiac transplant23,24. Survival following 
cardiac transplantation in Fontan patients is generally worse 
compared with other types of CHD136,137. Five-year survival 
ranges from 60 to 67%136–138.
Surgical innovations
Continual efforts are made to improve the surgical techniques 
used in Fontan surgery. Recently, a Y-shaped graft was 
proposed for the connection of the inferior vena cava to the 
left and right pulmonary artery139. Theoretically, this graft is 
more energetically favorable and provides better distribution of 
hepatic blood flow between the left and right pulmonary artery, 
distributing “hepatic factors” that may prevent the formation 
of intrapulmonary collaterals more equally. Worse energetic 
performance and pulmonary flow distributions in comparison 
with ECC connections have been noticed in practice140,141.
Fontan completion without cardiopulmonary bypass, particularly 
with the ECC technique, is an attractive option. However, 
experience is still limited and reported rates of conduit replace-
ment and outcomes following off-pump procedures differ 
across centers142–145.
Less-invasive surgical approaches such as lateral thoracotomy 
have been described in this population146. Hybrid procedures, 
which combine transcatheter and surgical approaches, have 
been implemented in the initial management of HLHS147. 
Long-term outcomes are favorable, and some centers have 
adopted this hybrid approach as the standard for selected 
patient populations148.
Remaining challenges
A contemporary Fontan strategy uses either the ILT or the 
ECC modification. Two large meta-analyses have recently 
compared surgical strategies and found no differences in early 
or late mortality and Fontan takedown between ECC and 
ILT33,149. Theoretical advantages of both techniques have been 
discussed extensively in the literature150,151. Further research 
should assess contemporary differences in outcomes between 
modifications and help guide the preferred procedure for 
future Fontan patients. This may include alternative concepts, 
like the Y-graft or combinations with external energy supply 
(pumps).
Remodeling of the SV, which is exposed to volume overload at 
birth and is volume-deprived following the TCPC procedure, 
is not very well understood. A better understanding of mecha-
nisms of remodeling during these stages and the interaction of 
ventricular size and function with the Fontan baffle function, 
pulmonary circulation, atrial function, and VA interaction is 
required to find better means to preserve cardiac function. 
The search for new targets for drugs that may help to preserve 
cardiac and circulatory function continues.
Some controversy regarding the timing of TCPC surgery exists. 
Proponents of early TCPC argue that a prolonged period of 
volume overload leads to adverse cardiac remodeling and 
reduced cardiac function152. Others argue that the Fontan 
circulation inherently leads to complications and that surgery 
should be delayed to reduce the amount of time in Fontan 
physiology153. Other factors to be considered are the tech-
niques used; ILT allows TCPC at lower body weight than ECC 
since small-sized conduits (<18 mm) need to be avoided152,154. 
Studies assessing the optimal timing of ECC procedures 
are currently being performed.
The effect of systemic to pulmonary venous and aortopul-
monary collaterals on the Fontan circulation remains poorly 
understood. These collaterals could provide some benefit in 
patients with a suboptimal Fontan circuit. How these collater-
als develop and why some patients seem more prone to this 
development remain to be determined. Increasing our under-
standing of the role of collaterals could help guide the selection 
of patients who will benefit from intervention. This requires 
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well-designed (multicenter) studies. Several treatment modali-
ties of PLE have been described in small series, including 
catheter-based strategies of both blood and lymphatic vessels 
and surgical re-implantation of the innominate vein into the 
common atrium155–159. More comprehensive analysis is needed 
to determine the efficacy and safety of these procedures.
Drug therapy has been shown to be able to decrease pul-
monary vascular resistance in the short-term, making this a 
promising therapy for the Fontan patient. However, currently, 
no long-term benefit has been demonstrated. The role of drug 
therapy in the Fontan circulation needs to be studied more 
extensively.
These questions require answers to make better-informed deci-
sions in the management of these challenging patients, who 
have some of the most severe kinds of CHD. We have an 
opportunity to help this growing patient population not just to 
survive but also to thrive and live full and satisfying lives.
Conclusions
The modern Fontan strategy has significantly transformed 
outcomes for patients with univentricular CHD. This has led 
to a large and growing population of Fontan patients surviving 
into adulthood. However, morbidity remains high and increases 
as this population ages and grows in proportion. Efforts to 
reduce morbidity and improve quality of life in these patients 
are ongoing. These efforts are focused on improving surgical 
techniques, developing novel diagnostic and therapeutic tools, 
and increasing our understanding of the highly abnormal 
Fontan physiology.
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